Novartis announces intention to separate Sandoz business to create a standalone company by way of a…
Novartis announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off.
The spin-off aims…
Read More...
Read More...
